FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain…
News
MHRA champions patient voices through new policy
Armada to combine with Brains Bioceutical in $750m deal
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Cordavis to stay in CVS Health after bifurcation of $117bn empire
Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic
Evommune signs $1.1bn licence deal with Hinova for EVO570
PharmatrophiX and Circular partner on neurodegenerative drugs
